+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biopharmaceuticals Contract Manufacturing Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Biopharmaceuticals Contract Manufacturing Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Biopharmaceuticals Contract Manufacturing Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 183 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5613012
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biopharmaceuticals Contract Manufacturing Market grew from USD 19.16 billion in 2024 to USD 20.16 billion in 2025. It is expected to continue growing at a CAGR of 5.19%, reaching USD 25.96 billion by 2030.

The biopharmaceutical contract manufacturing sector has emerged as a critical enabler for innovators seeking to bring complex therapies to market with speed and precision. As drug developers face mounting pressure to accelerate timelines, manage costs, and navigate stringent regulatory requirements, outsourcing production of active pharmaceutical ingredients, dosage formulations, and packaging has become indispensable. This report provides an in-depth executive summary of the evolving contract manufacturing landscape, highlighting key drivers, emerging trends, and strategic levers. By examining transformative shifts, the impact of United States tariffs effective in 2025, detailed segmentation insights, and regional dynamics, stakeholders can identify opportunities to optimize their supply chains. Furthermore, our analysis of leading service providers will inform decision-makers on competitive positioning. Through actionable recommendations rooted in current market realities, this summary equips executives with the foresight needed to maintain a competitive edge and deliver life-changing therapies efficiently.

Transformative Shifts Reshaping the Contract Manufacturing Landscape

The contract manufacturing arena is undergoing a profound transformation driven by convergence of advanced technologies, evolving regulatory frameworks, and shifting customer expectations. Personalized medicine initiatives are driving demand for small-batch, high-complexity therapies such as cellular treatments and gene therapies, compelling manufacturers to adopt modular and flexible facilities. Simultaneously, digitalization through artificial intelligence, machine learning, and data analytics is optimizing process development, improving yield, and reducing time-to-market. In addition, quality-by-design principles are increasingly mandated by regulators, prompting investment in real-time monitoring and predictive control systems.

Moreover, sustainability has moved from a niche focus to a boardroom imperative. Manufacturers are embedding green chemistry, single-use technologies, and waste reduction strategies into their operations to meet both environmental goals and cost objectives. These transformative shifts are redefining how service providers structure their offerings, where capacity is allocated, and how partnerships are forged. Consequently, decision-makers must stay attuned to these dynamics to capitalize on emerging opportunities and mitigate risks associated with legacy processes.

Cumulative Impact of United States Tariffs 2025 on Supply Chains

Effective January 1, 2025, the United States implemented a new tariff regime targeting imported ingredients, specialized equipment, and packaging materials critical to biopharmaceutical production. This measure has exerted upward pressure on input costs, forcing service providers to reassess sourcing strategies. For example, tariffs on high-grade stainless steel reactors and single-use bioreactor bags have increased capital expenditure, driving some manufacturers to explore alternative suppliers in regions with favorable trade agreements.

Furthermore, active pharmaceutical ingredients originating from select markets now incur additional duties, compelling developers to re-evaluate outsourcing agreements. As a result, nearshoring has gained traction, with manufacturers seeking plants closer to end markets to minimize tariff exposure and logistics complexity. In addition, long-term supply contracts are being renegotiated to include tariff pass-through clauses or fixed-price commitments that hedge against further trade policy volatility.

Collectively, these measures have accelerated a shift toward diversified supply bases and heightened collaboration between developers and CMOs. By proactively addressing tariff impacts, industry leaders can safeguard margins while maintaining the agility required to support complex, time-sensitive programs.

Key Segmentation Insights Driving Market Dynamics

A granular understanding of market segments reveals where demand is strongest and how service providers can tailor their capabilities. Based on service type, the market encompasses active pharmaceutical ingredient manufacturing, finished dosage formulation, and packaging services. Within active pharmaceutical ingredients, large-molecule biologics and small-molecule APIs each present unique technical and regulatory challenges. Meanwhile, finished dosage formulation splits into capsule and tablet manufacturing, with capsule production gaining momentum due to an uptick in hard-shell delivery systems. Packaging services further diversify into blister, bottle, and carton packaging, reflecting the need for varied compliance and patient-centric labeling options.

Turning to molecule type, the landscape divides between biologics and small molecules. The biologics category spans cellular therapies, monoclonal antibodies, and vaccines; within monoclonal antibodies, hybridoma-derived and transgenic platforms offer distinct production efficiencies. Small molecules remain dominated by branded drugs and generic competitors, emphasizing cost control and scale. Dosage form segmentation illustrates that oral forms-capsules and tablets-continue to drive volume, while parenteral forms such as infusions and injectables are pivotal for high-potency or specialty therapies. Topical forms, including creams, gels, and ointments, are leveraged for localized indications with customized delivery requirements.

Therapeutic application further refines market focus: cardiology services for hyperlipidemia and hypertension treatments, immunology production for fusion proteins and monoclonal antibodies, and oncology solutions for chemotherapy agents and hormonal therapies. Each category demands specialized facilities and tight quality controls. From an end-user perspective, biopharmaceutical companies lead outsourcing initiatives, supported by traditional pharmaceutical firms seeking to expand biologics capabilities. Lastly, product type segmentation distinguishes bulk ingredients-active ingredients and excipients-from combined products such as combo drugs and diagnostic or drug kits, as well as finished formulations that split into high-volume blockbuster productions and low-volume niche runs. This multi-layered analysis underscores opportunities for service providers to differentiate through depth of expertise, scale flexibility, and tailored customer engagement models.

Key Regional Insights Highlighting Growth Hotspots

Regional dynamics illustrate significant variability in capacity, cost structures, and regulatory environments. In the Americas, North American hubs benefit from proximity to large biopharma developers, streamlined regulatory pathways, and incentives for advanced therapy manufacturing. Latin American players are emerging as cost-effective alternatives, particularly for generic small-molecule production, as governments invest in life-science infrastructure.

Across Europe, Middle East & Africa, established centers in Western Europe continue to set global quality benchmarks with rigorous compliance standards, while Eastern European facilities offer competitive labor costs and expanding capacity. The Gulf region is rapidly advancing vaccine and biologics capabilities through public-private partnerships and sovereign wealth fund investments.

Meanwhile, the Asia-Pacific region represents the fastest-growing market, driven by strong government support, favorable economics, and a large biotech talent pool. China and India dominate small-molecule manufacture, whereas Singapore and South Korea focus on biologics, cell therapies, and integrated service models. This regional diversity enables developers to optimize portfolios based on cost, speed, and technical complexity requirements.

Competitive Landscape: Key Companies Driving Innovation and Capacity

The competitive landscape is shaped by a blend of global giants, specialized niche players, and emerging challengers. Leading contract manufacturers such as 3P Biopharmaceuticals and AGC Biologics have expanded capacity for single-use bioreactors and cell therapy suites, reflecting the surge in personalized treatments. AbbVie, Inc. and Boehringer Ingelheim International GmbH leverage in-house CDMO capabilities to ensure end-to-end quality control, while independent firms including Catalent, Inc., Lonza AG, and Samsung Biologics pursue strategic acquisitions to broaden their service portfolios and geographical reach.

Mid-tier providers such as Aenova Group GmbH, Aurobindo Pharma Limited, and Cambrex Corporation distinguish themselves through rapid turnaround times in small-molecule API and oral dosage manufacturing. Companies like Celonic AG and FUJIFILM Diosynth Biotechnologies focus on advanced viral vector production, catering to next-generation gene therapies. At the same time, KBI Biopharma Inc., Merck KGaA, and Thermo Fisher Scientific Inc. are investing in modular cleanroom solutions and continuous manufacturing technologies to drive process intensification.

Smaller specialized firms such as INCOG BioPharma Services, Inc., JRS PHARMA GmbH + Co. KG, Pressure BioSciences, Inc., ProBioGen AG, Rentschler Biopharma SE, Toyobo Co., Ltd., and WuXi Biologics, Inc. remain agile by focusing on niche segments-high-potency APIs, custom formulations, and regional partnerships. This diverse ecosystem fosters innovation, provides multiple entry points for developers, and encourages best-practice sharing across the industry.

Actionable Recommendations for Industry Leaders

To thrive in this complex environment, industry leaders should prioritize the following strategic actions. First, accelerate digitalization by integrating AI-driven process analytics, digital twins, and advanced process control to enhance yield, reduce variability, and shorten development cycles. Second, diversify supply chains by establishing multi-regional sourcing strategies and securing contingency agreements to mitigate tariff and geopolitical risks. Third, pursue strategic partnerships and co-development models with biotechnology innovators to access cutting-edge modalities while sharing development costs and risk.

In addition, investing in modular, single-use facility designs will enable rapid capacity scaling for personalized therapies and flexible production runs. Emphasize sustainable manufacturing practices-such as green chemistry and waste reduction-to meet environmental targets and strengthen corporate responsibility profiles. Finally, engage proactively with regulators to shape harmonized guidelines, expedite reviews, and achieve faster market access, particularly for advanced therapies that challenge traditional frameworks.

Conclusion: Embracing Change in Contract Manufacturing

The biopharmaceutical contract manufacturing sector stands at a pivotal juncture. Outsourcing remains the cornerstone strategy for achieving technical excellence and operational agility, yet navigating evolving tariffs, complex segmentation demands, and regional disparities requires deliberate planning. As digital tools, sustainability imperatives, and advanced therapy capabilities converge, service providers and sponsors must adopt a forward-looking mindset. By leveraging segmentation insights to align capacity with therapeutic trends, capitalizing on regional strengths, and collaborating with market leaders, stakeholders can unlock efficiencies and fuel innovation. Ultimately, those who anticipate change, embrace new technologies, and cultivate resilient partnerships will set the pace in delivering transformative treatments efficiently and reliably.

Market Segmentation & Coverage

This research report categorizes the Biopharmaceuticals Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Active Pharmaceutical Ingredient Manufacturing
    • Large Molecule
    • Small Molecule
  • Finished Dosage Formulation
    • Capsule Manufacturing
    • Tablet Manufacturing
  • Packaging Services
    • Blister Packaging
    • Bottle Packaging
    • Carton Packaging
  • Biologics
    • Cellular Therapies
    • Monoclonal Antibodies
      • Hybridoma
      • Transgenic
    • Vaccines
  • Small Molecules
    • Branded Drugs
    • Generic Drugs
  • Oral Dosage Forms
    • Capsules
    • Tablets
  • Parenteral Dosage Forms
    • Infusion
    • Injectable
  • Topical Dosage Forms
    • Creams
    • Gels
    • Ointments
  • Cardiology
    • Hyperlipidemia Drugs
    • Hypertension Drugs
  • Immunology
    • Fusion Proteins
    • Monoclonal Antibodies
  • Oncology
    • Chemotherapy
    • Hormonal Therapy
  • Biopharmaceutical Companies
  • Pharmaceutical Companies
  • Bulk Ingredients
    • Active Ingredients
    • Excipients
  • Combined Products
    • Combo Drugs
    • Kits
  • Finished Formulations
    • High Volume
    • Low Volume

This research report categorizes the Biopharmaceuticals Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Biopharmaceuticals Contract Manufacturing Market to delves into recent significant developments and analyze trends in each of the following companies:

  • 3P Biopharmaceuticals
  • AbbVie, Inc.
  • Aenova Group GmbH
  • AGC Biologics
  • Ajinomoto Co., Inc.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Celonic AG
  • FUJIFILM Diosynth Biotechnologies
  • INCOG BioPharma Services, Inc.
  • JRS PHARMA GmbH + Co. KG
  • KBI Biopharma Inc
  • Lonza AG
  • Merck KGaA
  • Pressure BioSciences, Inc. by Emergent Health Corp.
  • ProBioGen AG
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Thermo Fisher Scientific Inc.
  • Toyobo Co., Ltd.
  • WuXi Biologics, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Biopharmaceuticals Contract Manufacturing Market, by Service Type
8.1. Introduction
8.2. Active Pharmaceutical Ingredient Manufacturing
8.2.1. Large Molecule
8.2.2. Small Molecule
8.3. Finished Dosage Formulation
8.3.1. Capsule Manufacturing
8.3.2. Tablet Manufacturing
8.4. Packaging Services
8.4.1. Blister Packaging
8.4.2. Bottle Packaging
8.4.3. Carton Packaging
9. Biopharmaceuticals Contract Manufacturing Market, by Molecule Type
9.1. Introduction
9.2. Biologics
9.2.1. Cellular Therapies
9.2.2. Monoclonal Antibodies
9.2.2.1. Hybridoma
9.2.2.2. Transgenic
9.2.3. Vaccines
9.3. Small Molecules
9.3.1. Branded Drugs
9.3.2. Generic Drugs
10. Biopharmaceuticals Contract Manufacturing Market, by Dosage Form
10.1. Introduction
10.2. Oral Dosage Forms
10.2.1. Capsules
10.2.2. Tablets
10.3. Parenteral Dosage Forms
10.3.1. Infusion
10.3.2. Injectable
10.4. Topical Dosage Forms
10.4.1. Creams
10.4.2. Gels
10.4.3. Ointments
11. Biopharmaceuticals Contract Manufacturing Market, by Therapeutic Application
11.1. Introduction
11.2. Cardiology
11.2.1. Hyperlipidemia Drugs
11.2.2. Hypertension Drugs
11.3. Immunology
11.3.1. Fusion Proteins
11.3.2. Monoclonal Antibodies
11.4. Oncology
11.4.1. Chemotherapy
11.4.2. Hormonal Therapy
12. Biopharmaceuticals Contract Manufacturing Market, by End User
12.1. Introduction
12.2. Biopharmaceutical Companies
12.3. Pharmaceutical Companies
13. Biopharmaceuticals Contract Manufacturing Market, by Product Type
13.1. Introduction
13.2. Bulk Ingredients
13.2.1. Active Ingredients
13.2.2. Excipients
13.3. Combined Products
13.3.1. Combo Drugs
13.3.2. Kits
13.4. Finished Formulations
13.4.1. High Volume
13.4.2. Low Volume
14. Americas Biopharmaceuticals Contract Manufacturing Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Biopharmaceuticals Contract Manufacturing Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Biopharmaceuticals Contract Manufacturing Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. 3P Biopharmaceuticals
17.3.2. AbbVie, Inc.
17.3.3. Aenova Group GmbH
17.3.4. AGC Biologics
17.3.5. Ajinomoto Co., Inc.
17.3.6. Aurobindo Pharma Limited
17.3.7. Boehringer Ingelheim International GmbH
17.3.8. Cambrex Corporation
17.3.9. Catalent, Inc.
17.3.10. Celonic AG
17.3.11. FUJIFILM Diosynth Biotechnologies
17.3.12. INCOG BioPharma Services, Inc.
17.3.13. JRS PHARMA GmbH + Co. KG
17.3.14. KBI Biopharma Inc
17.3.15. Lonza AG
17.3.16. Merck KGaA
17.3.17. Pressure BioSciences, Inc. by Emergent Health Corp.
17.3.18. ProBioGen AG
17.3.19. Rentschler Biopharma SE
17.3.20. Samsung Biologics
17.3.21. Thermo Fisher Scientific Inc.
17.3.22. Toyobo Co., Ltd.
17.3.23. WuXi Biologics, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET MULTI-CURRENCY
FIGURE 2. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET MULTI-LANGUAGE
FIGURE 3. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULE MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY TABLET MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMULATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BLISTER PACKAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BOTTLE PACKAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARTON PACKAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING SERVICES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CELLULAR THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY HYBRIDOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY TRANSGENIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORAL DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY HYPERLIPIDEMIA DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY HYPERTENSION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BULK INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ACTIVE INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY EXCIPIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BULK INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMBINED PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMBO DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMBINED PRODUCTS, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY HIGH VOLUME, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY LOW VOLUME, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMULATION, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING SERVICES, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BULK INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMBINED PRODUCTS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMULATION, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING SERVICES, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BULK INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMBINED PRODUCTS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMULATION, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING SERVICES, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BULK INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMBINED PRODUCTS, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 140. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 141. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 142. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMULATION, 2018-2030 (USD MILLION)
TABLE 143. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING SERVICES, 2018-2030 (USD MILLION)
TABLE 144. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 145. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 146. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 147. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 148. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 149. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 150. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 151. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 152. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 154. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 155. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 156. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BULK INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 159. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMBINED PRODUCTS, 2018-2030 (USD MILLION)
TABLE 160. CANADA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 161. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 162. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 163. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMULATION, 2018-2030 (USD MILLION)
TABLE 164. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING SERVICES, 2018-2030 (USD MILLION)
TABLE 165. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 166. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 167. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 168. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 169. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 170. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 171. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 172. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 173. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 175. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 176. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 177. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 179. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BULK INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 180. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMBINED PRODUCTS, 2018-2030 (USD MILLION)
TABLE 181. MEXICO BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMULATION, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING SERVICES, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BULK INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMBINED PRODUCTS, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMULATION, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING SERVICES, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BULK INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMBINED PRODUCTS, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMULATION, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING SERVICES, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BULK INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMBINED PRODUCTS, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 247. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 248. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 249. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMULATION, 2018-2030 (USD MILLION)
TABLE 250. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING SERVICES, 2018-2030 (USD MILLION)
TABLE 251. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 252. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 253. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 254. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
TABLE 255. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 256. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ORAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 257. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PARENTERAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 258. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY TOPICAL DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 259. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 261. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY IMMUNOLOGY, 2018-2030 (USD MILLION)
TABLE 262. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 263. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 265. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY BULK INGREDIENTS, 2018-2030 (USD MILLION)
TABLE 266. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY COMBINED PRODUCTS, 2018-2030 (USD MILLION)
TABLE 267. CHINA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 268. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 269. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURING, 2018-2030 (USD MILLION)
TABLE 270. INDIA BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET SIZE, BY FINISHED DOSAGE FORMULATION, 2018-2030 (USD MILLION)
TABLE 2

Companies Mentioned

  • 3P Biopharmaceuticals
  • AbbVie, Inc.
  • Aenova Group GmbH
  • AGC Biologics
  • Ajinomoto Co., Inc.
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Celonic AG
  • FUJIFILM Diosynth Biotechnologies
  • INCOG BioPharma Services, Inc.
  • JRS PHARMA GmbH + Co. KG
  • KBI Biopharma Inc
  • Lonza AG
  • Merck KGaA
  • Pressure BioSciences, Inc. by Emergent Health Corp.
  • ProBioGen AG
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Thermo Fisher Scientific Inc.
  • Toyobo Co., Ltd.
  • WuXi Biologics, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), Type, Scale of Operation, Therapeutic Area, Region, and Segment Forecasts, 2025-2030 - Product Image

Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trend Analysis Report by Source, Service (Process Development), Drug Type (Biologics, Biosimilars), Type, Scale of Operation, Therapeutic Area, Region, and Segment Forecasts, 2025-2030

  • Report
  • 150 Pages
  • Global
From
Biopharmaceutical CMO & CRO Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Biopharmaceutical CMO & CRO Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Biopharmaceuticals Contract Manufacturing - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Biopharmaceuticals Contract Manufacturing - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Biopharmaceutical Process Analytical Technology Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Biopharmaceutical Process Analytical Technology Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Biologics Contract Manufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size and Key Geographical Regions - Product Image

Biologics Contract Manufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size and Key Geographical Regions

  • Report
  • 799 Pages
  • Global
From

About the Biopharmaceutical Contract Manufacturing Market

Biopharmaceutical Contract Manufacturing (CMO) is a service provided by specialized companies to biopharmaceutical companies. CMOs provide a range of services, from drug development and manufacturing to packaging and distribution. These services are tailored to the specific needs of the biopharmaceutical company, allowing them to focus on their core competencies. CMOs are able to provide a wide range of services, including process development, analytical testing, clinical trial materials, and commercial manufacturing. They also provide regulatory support, helping biopharmaceutical companies to navigate the complex regulatory landscape. CMOs are an important part of the biopharmaceutical industry, providing a cost-effective and efficient way to develop and manufacture drugs. Companies in the market include Lonza, Patheon, Boehringer Ingelheim, Catalent, and Ajinomoto Bio-Pharma Services. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.